Sovremennye vozmozhnosti mukoaktivnoy terapii
- 作者: Zaytsev A.A1, Okovityy S.V1, Kryukov E.V1
-
隶属关系:
- 期: 编号 14 (2015)
- 页面: 81-85
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288161
- ID: 288161
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
The article considers the principles of application of mucoactive drugs, which include mucokinetics, mucolytics, mucoregulators, as well as drugs reducing or maintaining the functional activity of the ciliary cells of the bronchial mucosa - stimulators of mucociliary clearance. There are two groups among mucolytics and mucoregulators: drugs realizing its effect mainly in the lumen of the bronchi (bromhexine, ambroxol, guaifenesin), and preparations normalizing the formation of bronchial secretions (acetylcysteine, dornase alpha). In cases when patients have several symptoms of affect of the tracheobronchial tree (eg, cough, presence of viscous sputum, bronchial obstruction), it is reasonable to use the combined mucoactive drugs such as Ascoril containing mucolytic (Bromhexine), mucolytic/mucokinetic (guaifenesin) and ß2-adrenoagonist (salbutamol).
全文:
参考
- Оковитый С.В., Анисимова Н.А. Фармакологические подходы к противокашлевой терапии. Русский медицинский журнал. 2011;23:1150-58.
- Зайцев А.А., Оковитый С.В. Кашель: дифференциальная диагностика и фармакотерапия. Тер. архив. 2014;12:85-91.
- Клячкина И.Л. Муколитическая терапия в программе лечения хронической обструктивной болезни легких. Справочник поликлинического врача. 2006;9:35-40.
- Клячкина И.Л. Лечение кашля при острой респираторной инфекции и гриппе у пациентов группы риска. Фарматека. 2010;5:125-32.
- Ровкина Е.И. Эффективность и безопасность отхаркивающего лекарственного средства Аскорил. Новые СПб. врачебные ведомости. 2000;4;54-5.
- Ainapure S., Desai A., Korde K. Efficacy and safety of Ascoril in the management of cough -National Study Group report. J. Indian Med. Assoc. 2001;99:111-14.
- Prabhu Shankar S., Chandrashekharan S., Bolmall C.S., Baliga V. Efficacy, safety and tolerability of salbutamol + guaiphenesin + bromh-exine (Ascoril) expectorant versus expectorants containing salbutamol and either guaiphenesin or bromhexine in productive cough: a ran-domised controlle comparative study. J. Indian Med. Assoc. 2010;108:313-20.
- Zheng J., Wen F., Bai C., et al. (PANTHEON study group). Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2014;2(3):187-94.
补充文件
